

This listing of claims will replace all prior versions, and listings, of claims in our amendments or responses to Office actions.

**Listing of Claims:**

1. (Currently amended) A method of treating a human subject experiencing a physiological disorder comprising administering an effective amount of an agonist or antagonist of DCRS5 (SEQ ID NO: 2)~~NOs:1 or 2~~ or of p19 (SEQ ID NOs:5 or 6),  
wherein the antagonist is a binding composition derived from the antigen binding site of  
an antibody, or is a nucleic acid, wherein the disorder comprises:
  - a) rheumatoid arthritis;
  - b) asthma or allergy;
  - c) chronic obstructive pulmonary disorder (COPD);
  - d) an interstitial lung disorder;
  - e) an inflammatory bowel disorder (IBD); or
  - f) an inflammatory skin disorder.
2. (Withdrawn) The method of Claim 1, wherein the skin disorder is:
  - a) psoriasis; or
  - b) atopic dermatitis.
3. (Previously presented) The method of Claim 1, wherein the IBD is:
  - a) Crohn's disease; or
  - b) ulcerative colitis.
4. (Withdrawn) The method of Claim 1, wherein the interstitial lung disorder is:
  - a) idiopathic pulmonary fibrosis;
  - b) eosinophilic granuloma; or
  - c) hypersensitivity pneumonitis.

5. (Currently amended) The method of Claim 1, wherein the antagonist comprises a binding composition derived from the antigen binding site of an antibody that specifically binds to[:]

- a) DCRS5 (SEQ ID NO:2); or
- b) p19 (SEQ ID NO:6).

6. (Previously presented) The method of Claim 5, wherein the binding composition comprises:

- a) a polyclonal antibody;
- b) a monoclonal antibody;
- c) a humanized antibody; or
- d) an Fab, Fv, or F(ab')<sub>2</sub> fragment.

7. (Canceled)

8. (Currently amended) The method of Claim 1, wherein the ~~agonist or~~ antagonist comprises a nucleic acid.

9. (Previously presented) The method of Claim 8, wherein the antagonist comprises:

- a) an antisense nucleic acid; or
- b) an RNA interference nucleic acid.

10 - 17. (Canceled)